Abstract | BACKGROUND: METHODS: Analysis of the clinicopathologic features, treatment regimens, and overall survival of 209 lung adenocarcinoma patients who had been detected for TTF-1 expression and received consecutive treatments in the Affiliated Hospital of Qingdao University. RESULTS: TTF-1 expression was positive in 166 (79%) and negative in 43 (21%) patients who were reviewed. Moreover, there was no significant difference between the clinicopathologic features of TTF-1 positive and TTF-1 negative tumors. In the multivariable review, the overall survival of TTF-1 positive tumor patients was significantly longer than that of TTF-1 negative tumor patients [22.7 vs. 11.8 months (P<0.0001)], increasing the prognostic effect of Karnofsky performance status and receiving first-line chemotherapy or targeted therapy. Positive TTF-1 and negative TTF-1 patients receiving pemetrexed-based chemotherapy improved the duration of treatment compared to those receiving non- pemetrexed chemotherapy. CONCLUSIONS: TTF-1 expression was associated with an improved survival in patients with advanced lung adenocarcinomas. Both patients, either TTF-1 positive or negative, could benefit from the first-line chemotherapy or pemetrexed treatment option. However, as discovered by our investigation, TTF-1 cannot forecast a portion of the lung adenocarcinomas that had a selective sensitivity to pemetrexed.
|
Authors | Xueying Li, Ling Yin, Yamei Zhao, Man He, Qi Qi, Yang Sun, Hongmei Li, Matthew Evison, written, AME Lung Cancer Collaborative Group |
Journal | Translational lung cancer research
(Transl Lung Cancer Res)
Vol. 9
Issue 1
Pg. 82-89
(Feb 2020)
ISSN: 2218-6751 [Print] China |
PMID | 32206556
(Publication Type: Journal Article)
|
Copyright | 2020 Translational Lung Cancer Research. All rights reserved. |